Steady growth, margin sacrifice starts next quarter
REPCO reported 7.4% revenue growth and 5.6% profit growth—modest by any measure. But the real story is the pre-announced 10-12 bps spread compression coming in Q2 to fund aggressive growth and customer retention. The market has already priced in skepticism.
REPCO's Q1 earnings tell a story of steady but constrained growth competing against rising headwinds. Revenue grew 7.4%, profit 5.6%, both in single digits. The numbers are clean, but the tension is visible on two fronts: Q1 disbursements were essentially flat year-on-year at ₹843 crore (vs ₹829 crore prior year, +1.7%), contradicting an aggressive growth narrative; and management has pre-announced a 10-12 basis-point spread compression in Q2 and beyond to fund aggressive lending and arrest rising balance-transfer attrition. The market has already rendered its verdict—the stock fell 2.43% on day 1 and 5% by day 3, and sits 21.6% below its all-time high on sustained selling. The question now is whether REPCO's structural improvements (IT transformation, NPA bifurcation, verticalization) can justify the near-term margin sacrifice.
The quarter in numbers: what the result actually shows
₹467.7 Cr
+7.4% YoY (modest by growth HFC standards)
₹121.6 Cr
+5.6% YoY (filed result; call stated ₹114 Cr)
5.4%
Stable, but facing 10-12 bps compression next quarter
₹843 Cr
+1.7% YoY (flat; seasonal disruptions cited)
₹15,990 Cr
+8.9% YoY (on track for 13-14% FY27 target)
8.3%
Stable via ₹600 Cr NHB refinance (₹106 Cr availed)
The profit disclosure gap (₹121.6 Cr filed vs ₹114 Cr stated on the call) deserves immediate attention. Management disclosed ₹114 crore in the opening remarks but the filed result shows ₹121.6 crore—a 6.7% discrepancy. This suggests either a provisional disclosure on the call or adjustments finalized post-filing. While not a material restatement, it raises precision concerns about management's ability to communicate the final number accurately. For a financial services company, this matters.
Management's key claims versus what holds up
Disbursement growth on track for ₹5,000 Cr annual target
Q1 ₹843 Cr is +1.7% YoY (flat). June-August recovery claimed but no specific numbers disclosed. July and August said to be 'very good' and 'strong' but unverified on the call.
Contradicted (Q1 flatness)
Asset quality improved YoY, GNPA stable
GNPA 2.7% June 2026 vs 2.6% March 2026 (QoQ worsened). YoY better (vs ~3% June 2025). Staff disruptions in April-May cited as cause.
Mixed (YoY better, QoQ worse)
Cost of funds positioned to reduce via NHB refinance
₹600 Cr NHB facility obtained; ₹106 Cr drawn in early August. Cost stabilized at 8.3%, not yet reduced. Plausible post-quarter impact.
Supported (stabilized, reduction pending)
NIM 5.4%, spread 3.4% maintained
NIM/ROA figures align with filed result (NPM 26%, ROA 2.9%). But spread will compress 10-12 bps Q2+ for growth/retention.
Supported (for Q1; future at risk)
Aggressive growth push; ₹5,000 Cr disbursement confident
MD stated 'pretty sure and confident' but Q1 flat YoY growth. Recovery tied to June-August (unverified). Seasonal staffing disruptions cited; now settled.
Partially answered (Q1 weak, recovery unverified)
The disbursement flatness is the quarter's buried tension. Management frames it as seasonal (April-May staff transfers and promotions disrupting Q1), claims June onward recovered, and asserts the ₹5,000 Cr annual target and ₹1,200–1,250 Cr Q2 guidance are on track. But analysts pressed for June and July numbers to validate momentum, and management declined to disclose specifics (citing price sensitivity). This shifts the burden of confidence to management's assurance—credible given 25-year tenure, but unverified on the call and risky if Q2 misses the ₹1,200 Cr bar.
What changed on this call
Guidance maintained, not raised — FY27 ₹5,000 Cr disbursement, 13-14% AUM growth, ₹40 Cr NPA reduction reaffirmed from prior call. No upgrade despite optimization narrative.
Spread sacrifice explicitly pre-announced — MD committed to compress 10-12 bps in Q2+ for aggressive disbursement growth and balance-transfer retention. A downgrade from margin-protection posture.
NPA strategy bifurcated into soft and chronic — New approach: separate 1,000–1,100 soft-NPA accounts (recent slippages Apr 2025–Jun 2026) under specialist recovery team; chronic accounts (old defaults) under SARFAESI. Credible targeting, not new guidance.
Geographic focus narrowed to non-TN expansion — Prioritizing Andhra Pradesh, Telangana, Karnataka, then Maharashtra, Rajasthan, Gujarat. TN still 57% of AUM; expansion plan detailed but not quantified with targets.
Accounting method encashment-basis for 3-4 quarters — AUM/interest recognized only after cheque clears. Standard in industry; adds opacity to prior-quarter comparisons. No restatement disclosed.
The most significant shift is the pre-announced margin sacrifice. MD openly stated: "For aggressive disbursements and controlling BT out, I need to sacrifice some portion on spread." This is not a passive observation—it's a strategic choice to prioritize growth and customer retention over near-term profitability. Combined with rising balance-transfer attrition (evidenced by June GNPA spike tied to staff disruptions), it signals management is in defensive posture on market share, not a confident growth expansion.
The bull-bear ledger
Bull: AUM growth 8.9% YoY and on track for 13-14% FY27 target. Volume trajectory is solid if Q2 validates.
Bull: Asset quality improved YoY despite Q1 seasonal spike. GNPA ₹427 Cr (June) vs ₹485 Cr (June 2025). Bifurcated NPA strategy (soft vs chronic) is detailed and credible.
Bull: Structural improvements (IT transformation 2 phases complete, verticalization by function, API integrations) stabilizing operations. Materialization in 2H remains to be seen.
Bull: Cost of funds stable at 8.3% via ₹600 Cr NHB refinance. Funding cost buffer in place even as lending rates face pressure.
Bear: Q1 disbursement flat YoY at ₹843 Cr (+1.7%). Contradicts aggressive posture. Q2 target ₹1,200–1,250 Cr and annual ₹5,000 Cr at execution risk if momentum doesn't materialize.
Bear: Spread compression 10-12 bps pre-announced for Q2+. ROA/ROE pressure visible if volume growth doesn't offset margin decline. Management confident but near-term profitability under pressure.
Bear: Pricing power erosion. Competitor rates 8.5–8.75% vs REPCO 10.75–11%. Forces REPCO into non-salaried/informal segment (53.5% of book) with higher underwriting risk and limited addressable market.
Bear: PAT understated on call (₹114 Cr vs ₹121.6 Cr filed). Raises transparency concerns. Plus, encashment-basis accounting (3-4 quarters) adds opacity to comparisons.
Bear: Geographic concentration high (TN 57% of AUM). Expansion plan detailed but execution risk if non-TN states don't ramp fast enough.
Ranked risks — what should concern a holder
Execution on ₹5,000 Cr FY27 disbursement target
HighQ1 flat YoY (+1.7%). Annual target requires ₹5,000 Cr / 4 quarters = ₹1,250 Cr avg. Q2 guidance ₹1,200–1,250 Cr is just the floor. If Q2 misses or June-August recovery doesn't materialize, full-year ₹5,000 Cr slips. Jeopardizes 13-14% AUM growth target and shareholder confidence in guidance credibility.
Margin compression (10-12 bps announced) vs volume offset
HighMD pre-committed to sacrifice 10-12 bps spread for growth and retention. If disbursement doesn't grow proportionally or faster, ROA and ROE will compress post-Q1. Q1 ROA 2.9%, ROE 12.7% already modest; further erosion limits upside multiple. Investors pricing for margin squeeze but awaiting proof of volume leverage.
Pricing power erosion in competitive HFC market
HighCompetitors at 8.5–8.75% vs REPCO 10.75–11% forces REPCO into higher-risk, lower-scale non-salaried segment (53.5% of book). Caps growth ceiling and increases credit risk. Unaddressable gap in vanilla segment limits total addressable market.
Asset quality deterioration (QoQ GNPA increase despite YoY improvement)
MediumGNPA 2.7% (June) vs 2.6% (March) is QoQ worsening. Staff disruptions cited as temporary, but June spike signals vulnerability. Recovery target to ₹405 Cr by Q2 (from ₹427 Cr) critical to validate Q1 as seasonal anomaly. If not met, asset quality concern escalates. NPA <2% target by March 2027 at risk.
BT (balance transfer) attrition and retention cost pressure
MediumJune BT spike visible in data; new retention schemes add cost. As REPCO loses customers to lower-rate competitors, cost of retention increases (rate concessions, schemes). Spread sacrifice already pre-announced; additional BT drag will worsen ROA further. Hidden in Q1 results; will show in Q2.
Geographic concentration (TN 57% of AUM) expansion execution
MediumExpansion plan named (AP, TG, KA, west India) but not quantified. 12–13 new branches FY27 is incremental. If non-TN states don't reach critical mass, book remains vulnerable to TN-specific shocks (monsoon, local credit cycles, regulatory changes).
Accounting practice opacity (encashment-basis, PAT discrepancy)
Low-MediumPAT ₹114 Cr stated vs ₹121.6 Cr filed (6.7% gap) and encashment-basis recognition (3-4 quarters) make comparisons opaque. Not material, but erodes trust in management precision. Governance flag for institutional investors.
How the market is positioned — and what it tells us
The post-result price action confirms the fundamental skepticism. REPCO opened at ₹376.35 (pre-result close) and fell 2.43% on day 1 (announced result), then a further -5% by day 3. The stock now trades at ₹357.55, down 21.6% from its all-time high of ₹455.9. More tellingly, it sits below all key moving averages (SMA20 ₹384.61, SMA50 ₹394.16, SMA200 ₹397.02) and the RSI is at 26.6—deeply oversold territory. Volume is normal, not panic selling, but the directional trend is bearish.
Institutional flows tell a different story. FII ownership fell 102 basis points to 12.35% (from 13.37% prior quarter), while DII added 180 basis points to 26.08% (from 24.28%). This is classic de-risking by foreign investors amid margin concerns and unvalidated growth guidance, offset by domestic buying—likely mutual funds viewing the drawdown as an opportunity on the structural story (IT, NPA bifurcation). Promoter stake unchanged at 37.13%.
The gap between where the stock trades (oversold) and where the fundamentals sit (steady but pressured) suggests two camps: one betting that Q2 misses guidance and margin compression deepens; another betting Q2 validates recovery and the margin sacrifice is a deliberate (not forced) investment in market share. The delivery ratio of 60.4% on day 1 indicates conviction selling, not just profit-taking. This is not a bounce-trade setup—it's a conviction bear positioning REPCO against market consensus.
The debate
What to watch next
1 · Q2 disbursement: validate ₹1,200–1,250 Cr guidance
This is the credibility lynchpin. If Q2 hits ₹1,200 Cr or above, June-August recovery narrative holds and FY27 ₹5,000 Cr target remains on track. If Q2 falls short (say, ₹1,100 Cr or below), the quarterly average needed to hit ₹5,000 Cr rises above ₹1,280 Cr—highly unlikely for Q3-Q4. Miss here and the stock breaks down further.
2 · GNPA recovery to ₹405 Cr by Q2 (March level) or deterioration signal
June GNPA spike (₹427 Cr, 2.7%) is attributed to staff disruptions—a transient excuse if it recovers to ₹405 Cr (2.6%) by Q2. Failure to recover signals structural asset quality deterioration, not seasonal noise. This makes or breaks the 'bifurcated soft/chronic strategy' credibility. Also watch Stage 2 (currently 7.2%) for further deterioration.
3 · Spread compression quantum and ROA impact in Q2
Q1 spread 3.4%, NIM 5.4%, ROA 2.9%. Management pre-committed to 10-12 bps spread compression in Q2+. Watch whether Q2 realized spread is 3.28–3.30% (the lower end of 10-12 bps) or steeper, and whether ROA holds above 2.7% (reflecting volume growth offset) or dips below 2.5% (showing no offset). This tells us if margin sacrifice is strategic choice or forced necessity.
4 · NHB refinance drawdown and cost-of-funds traction (₹494 Cr remaining)
Management tapped ₹106 Cr of the ₹600 Cr NHB facility in early August. Watch the drawdown trajectory in Q2-Q3. If drawdown pace slows or the facility doesn't reduce cost below 8.3%, the funding cost buffer assumption weakens and spread compression becomes even more painful.
5 · Non-TN geographic expansion progress (12–13 branches, AP/TG/KA focus)
Expansion is detailed on the call but not quantified with branch count targets or AUM targets per state. Watch Q2-Q3 for evidence of new branch productivity and mix shift. If non-TN AUM growth accelerates above TN growth (currently TN still 57%), the concentration risk starts to unwind.
The single number to track
Q2 FY27 disbursements: ₹1,200–1,250 Cr. This one quarterly number determines whether REPCO's full-year guidance holds or breaks. Hit it, and the ₹350 stock level is a buying opportunity; miss it, and the stock revisits ₹320–330. Everything else—margin sacrifice, asset quality, geographic expansion, guidance credibility—hinges on whether REPCO can actually grow lending volume in a competitive market where it has lost pricing power. So far, Q1 suggests skepticism is warranted.
REPCO Home Finance is not in crisis. Profitability is real (₹121.6 Cr), balance sheet is solid, structural improvements are underway, and the long-term market opportunity for housing finance in India is real. But this quarter is not the inflection point bulls hoped for. Instead, it's a steady state with visible near-term pressure: flat disbursement growth, pre-announced margin sacrifice, and pricing power erosion. The stock's 21.6% drawdown from ATH likely reflects this realism.
The market is daring REPCO to prove it can grow volume even as spreads compress and competitors undercut by 200+ basis points. That's not an unreasonable demand—execution determines the answer. But on the evidence of Q1 (flat disbursement growth, unverified recovery claims, and a pre-announced margin sacrifice ahead), the burden of proof is on management. Wait for Q2 results to validate the recovery narrative before committing fresh capital. The oversold technical condition is tempting, but fundamentally, REPCO is a hold—not a buy, not a sell. The next quarter answers the question.
Repco Home Finance Q1FY27: consol PAT +5.6% YoY to ₹121.6 Cr, margins steady
PAT +5.63% YoY · revenue +6.23% · margins flat
₹467.7 Cr
+6.23% YoY
₹121.62 Cr
+5.63% YoY
25.99%
-0.1pp YoY
₹19.44
Repco Home Finance's consolidated net profit rose 5.6% YoY to ₹121.62 Cr in Q1 FY27 (from ₹115.14 Cr), on total income of ₹467.90 Cr, up 6.2% YoY from ₹440.70 Cr. The standalone-basis net profit (before the ₹7.47 Cr share of associate Repco Micro Finance) was ₹114.15 Cr, up 5.7% YoY — the figure management's own press release headlines as '₹114 Cr, up 5.6%', which actually blends the standalone rupee amount with the consolidated growth rate. Net profit margin held roughly flat at ~26.0% of total income versus 26.13% a year ago. Sequentially, PAT fell 10.0% QoQ from ₹135.18 Cr and NPM compressed from 29.76%, but that Q4FY26 base was lifted by a one-off ₹14.4 Cr deferred tax reversal (Note 7, related to the company's Special Reserve under Section 36(1)(viii)) — stripping that out, the underlying quarterly run-rate is stable rather than declining, so the QoQ dip is a base-effect artifact and the YoY print is the more representative read.
Q1 FY-2027 vs prior quarters
We found no analyst/brokerage consensus estimate for this quarter in public sources, so the print cannot be graded against Street expectations (vsStreet: unknown). Against management's own FY27 guidance from the Q4FY26 call — ~₹5,000 Cr disbursements, AUM growing to ₹18,000 Cr, spread of 3.2-3.25%, and Stage 2 assets below 5% — this filing discloses no AUM, disbursement or Stage 2 figures, only asset-quality ratios (GNPA 3.33%, NNPA 1.91%, or 2.67%/1.23% excluding interest accrued and EIR adjustments) and a net worth of ₹4,018.65 Cr with a debt-equity ratio of 3.01x; it is too early in the year to say whether the full-year AUM/disbursement targets are on track. On the same day as results, the company announced new director appointments and joint statutory auditors, alongside a quieter run of debt-market activity through the quarter — redemption of ₹50 Cr and issuance of ₹75 Cr of commercial paper in late June, and a senior management retirement flagged June 30 — none of which show up as one-offs in this quarter's P&L.
The stock went into the print at ₹376.35, down 10.3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated total revenue from operations ₹467.70 Cr, up 6.2% YoY (₹440.26 Cr) and up 3.1% QoQ (₹453.52 Cr).
Consolidated EPS ₹19.44 (basic & diluted) vs ₹18.40 a year ago — standalone EPS ₹18.25 vs ₹17.26.
Management projects a disbursement target of approximately Rs. 5,000 Crores for the current financial year, aiming to increase Assets Under Management (AUM) to Rs. 18,000 Crores, with an aspiration to reach Rs. 25,000 Crores AUM in the next two years. They are focusing on aggressive disbursement growth to counter loan
W1
AUM/disbursement pace toward management's FY27 target of ₹18,000 Cr AUM (~₹5,000 Cr disbursements) — no AUM figure disclosed this quarter; watch Q2 for the first checkpoint.
W2
Stage 2 asset trend toward management's sub-5% target — not disclosed this quarter, only GNPA 3.33%/NNPA 1.91% given.
W3
Spread trajectory toward the 3.2-3.25% target, particularly any 10-15 bps cost-of-funds relief management flagged from a new NHB refinance facility.
Modest growth, margin sacrifice ahead, execution uncertain
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Maintained prior FY27 guidance (₹5,000 Cr disbursal, 13-14% AUM growth); asset quality improved YoY but deteriorated QoQ. Disclosed ₹114 Cr PAT on call vs filed ₹121.6 Cr (6.7% understatement).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Repco is executing on structural transformation (IT, verticalization, NPA management) with decent YoY growth (7.4% revenue, 5.6% PAT). However, Q1 disbursement growth is flat, contradicting aggressive posture; management pre-announced 10-12 bps spread compression next quarter to fund growth and retain customers amid rising BT attrition. Long-term AUM trajectory (8.9% YoY, targeting 13-14% FY27) is sound, but near-term profitability pressure and uncertain execution on ₹5,000 Cr FY27 target merit caution. Key risk: pricing power erosion in competitive HFC market limits upside.
₹467.7 Cr
Revenue · +7.4% YoY₹121.6 Cr
Reported PAT · +5.6% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Net profit ₹114 Cr YoY growth steady
OVERSTATEDFiled result shows ₹121.6 Cr (6.7% higher than stated on call)
Disbursements growing, on track for ₹5,000 Cr
MISSQ1 ₹843 Cr vs prior year ₹829 Cr = +1.7% (essentially flat); recovery only claimed for June onwards, not verified on call
Asset quality improved YoY, GNPA stable
MixedGNPA 2.7% June 2026 vs 2.6% March 2026 (QoQ worsened); YoY better than June 2025 (~3%), but staff disruptions cited for June spike
Cost of funds 8.3%, positioned to reduce via NHB refinance
MET8.3% stated; ₹600 Cr NHB facility obtained, ₹106 Cr already availed in early August; plausible stabilization, not yet reduction visible
NIM 5.4%, spread 3.4% maintained
METDelivered NPM 26.0% and ROA 2.9% align with profitability disclosed; spread will compress 10-12 bps going forward for growth/retention
Earnings quality
What changed since the last call
Guidance maintained, not raised
NeutralFY27 ₹5,000 Cr disbursement guidance unchanged vs prior FY26 call; AUM 13-14% growth reaffirmed; no guidance upgrade despite optimization narrative.
Spread sacrifice announced
DowngradeMD pre-committed to compress spread 10-12 bps in Q2+ for aggressive growth & BT retention, shifting from margin protection to growth-at-cost strategy.
Q1 disbursement flat vs prior year
Downgrade₹843 Cr Q1 vs ₹829 Cr YoY (+1.7%); contradicts 'aggressive' posture; seasonal (April-May staffing disruptions) cited but recovery unverified on call.
NPA strategy bifurcated
NeutralNew soft (recent slippage) vs chronic (old defaulters) NPA targeting; 1,000-1,100 soft accounts under specialist recovery team; credible approach, not new guidance.
Geographic focus narrowed
NeutralPrioritizing non-TN states (AP, TG, KA, Maharashtra, Gujarat, Rajasthan) while TN remains 57% of book; expansion plan detailed, not quantified with targets.
The Q&A
Moderate analyst pressure on share price underperformance (Gurumurthy HNI heavily criticized), competitive pricing limits (rates 10.75-11% vs peers 8.5-8.75%), BT attrition (Rajiv Mehta). Management held firm on strategy (no diversification beyond HFC, targeting non-salaried/informal segment, not PSU vanilla). Tone defensive on shareholder value, but transparent on trade-offs (spread sacrifice, retention costs).
Pricing power & shareholder returns — Gurumurthy T., HNI
PartialCost of funds 8.3% vs bank CASA 3-3.5%; targeting non-salaried/informal borrowers at higher risk, not PSU vanilla segment. No plans to diversify; HFC license restricts scope. Aggressiveness will come from volume, not rate cuts.
Disbursement mechanics — Prithviraj Patel, Investec
AnsweredMonth-end carry-forward ₹35-40 Cr routine cycle. June specifically affected; reported numbers business-as-usual; no material re-statement impact.
Growth momentum validation — Rajiv Mehta, Yes Securities
PartialClaimed June good, July better, August strong; on track for ₹1,200 Cr+ and ₹5,000 Cr annual. Cannot disclose specific numbers (price-sensitive); confidence based on momentum observation.
Asset quality deterioration — Sanjana Sivaram, DAM Capital
AnsweredApril-May staff transfers/promotions disrupted June; isolated incident. Bifurcating NPA into soft (1,000-1,100 recent accounts) and chronic; targeting 50% soft reduction (₹70-75 Cr) + SARFAESI on chronic; goal <2% NPA by March 2027.
Transformation roadmap — Pulavarthi Kiran, Pulavarthi Fins
AnsweredIT transformation 2 phases complete; mobile app, API integrations (Perfios/CERSAI/CIBIL) reduce turnaround. Verticalization (separate recoveries, sales, NPA management verticals) replaces generalist branch model. Adding 12-13 branches FY27 focusing AP, TG, KA, west India.
Q1 disbursement flatness — Nidhesh Jain, InvesTech
AnsweredSeasonal; April-May transfers/promotions always slow Q1. Now settled. June strong, July very good, August tracking well. Making up Q1 backlog. ₹5,000 Cr FY27 on track.
Accounting method change — Abhijit Tibrewal, Motilal Oswal
AnsweredYes, using encashment-basis for 3-4 quarters; only after cheque clears do we book interest and add to AUM. Industry-standard practice.
Guidance
FY2027: ₹5,000 Cr disbursements (unchanged from FY26 guidance)
MediumQ1 flat YoY; recovery claimed for June onward but unverified. Seasonal pattern (April-May disruptions) cited; Q2 target ₹1,200-1,250 Cr to validate momentum.
Spread 3.4% (June); expected 10-12 bps compression Q2+ for growth/retention
HighMD explicitly pre-announced spread sacrifice to fund disbursement growth and arrest BT attrition. NIM 5.4% will face downward pressure from compressed spread.
Cost of funds stable at 8.3% via NHB refinance ₹600 Cr (₹106 Cr availed, ₹494 Cr committed)
HighRefinance facility locked in; balances aggressive pricing strategy by stabilizing funding cost. Further rate reduction negotiated with existing bankers but not quantified.
Risks the call surfaced
Execution risk (FY27 target)
High₹843 Cr Q1 FY27 vs ₹829 Cr Q1 FY26 = +1.7% (essentially flat). MD claimed June onward recovery but no specific numbers disclosed on call. If Q2-Q4 don't accelerate meaningfully, ₹5,000 Cr annual target at risk.
Margin compression
HighMD pre-announced 10-12 bps spread compression in Q2+ to fund aggressive disbursement growth and arrest BT attrition (June BT spike vs March). Spread 3.4% (June) will compress; ROA/ROE impact unclear if volume doesn't grow proportionally.
Pricing power erosion
MediumCompetitor banks/HFCs offering home loans at 8.5-8.75% vs Repco 10.75-11%. MD defended by targeting non-salaried/informal (53.5% of book) with higher underwriting standards. But this segmentation caps addressable market and growth ceiling.
Asset quality deterioration (near-term)
MediumGNPA ratio 2.7% (June 2026) vs 2.6% (March 2026) represents slight QoQ deterioration despite YoY improvement narrative (2.7% June 26 vs ~3% June 25). MD attributed to April-May staff transfers/promotions affecting collection. Recovery to March level (₹405 Cr from ₹427 Cr) targeted by Q2.
Customer concentration / Geographic concentration
MediumTamil Nadu accounts for 57% of book (implicit ₹9,100+ Cr of ₹15,990 Cr AUM). While diversified by borrower type (53.5% non-salaried, 46.5% salaried), geographic concentration is high. Telangana growing well; rest of states showing uneven growth.
Accounting/disclosure risk
LowCall disclosed ₹114 Cr PAT (Q1 FY27) vs filed result ₹121.6 Cr (6.7% higher). Encashment-basis for AUM/interest recognition in place for 3-4 quarters; no disclosure of prior-quarter restatement impact. Makes YoY/QoQ comparisons opaque and raises transparency concerns.
Management
Score 6/10. Candid on trade-offs (spread sacrifice, BT costs); defensive on shareholder value criticism; transparent on seasonal patterns & structural challenges. Avoids specific numbers on June/July (claimed price-sensitive); PAT understatement on call (₹114 vs ₹121.6 filed) raises disclosure precision concerns. Met prior-year guidance broadly (AUM growth, cost management, ROE/ROA levels consistent). Q1 disbursement flat YoY contradicts aggressive posture; staff disruption cited as seasonal but June-August recovery unverified on call. NPA reduction strategy detailed (bifurcated soft/chronic approach) credible but unproven; target ₹405 Cr by Q2 critical.
1 · Q2 FY27
Target to recover Q1 NPA (₹427 Cr) to March level (₹405 Cr); confirm ₹1,200-1,250 Cr disbursements on track
2 · Sep 2026
Target GNPA reduction to ₹400 Cr; validate ₹40 Cr annual reduction guidance holding
3 · FY27 (full year)
Achieve ₹5,000 Cr disbursement, 13-14% AUM growth (₹18,000 Cr target); geographic expansion (AP, TG, KA, Maharashtra, Gujarat, Rajasthan)
Key risk: pricing power erosion in competitive HFC market limits upside.